{
    "clinical_study": {
        "@rank": "55229", 
        "arm_group": [
            {
                "arm_group_label": "PRT064445", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of\n      several blood thinner drugs on laboratory tests.  The study also is evaluating the blood\n      levels of PRT064445 given at different doses."
        }, 
        "brief_title": "Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "detailed_description": {
            "textblock": "A randomized, double-blind, vehicle-controlled study to assess the safety, tolerability,\n      pharmacokinetics, and pharmacodynamics of intravenously administered PRT064445 after dosing\n      to steady state with one of four direct/indirect fXa inhibitors in healthy volunteers"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy men or women between the ages of 18 and 45 years old\n\n        Exclusion Criteria:\n\n          -  History (including family history) or symptoms of, or risk factors for bleeding\n\n          -  History (including family history) of or risk factors for a hypercoagulable or\n             thrombotic condition\n\n          -  Absolute/relative contraindication to anticoagulation or treatment with specific\n             anticoagulants\n\n          -  History of major surgery, severe trauma or bone fracture within 3 months prior to\n             dosing; or planned surgery within 1 month after dosing."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "144", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01758432", 
            "org_study_id": "12-502"
        }, 
        "intervention": [
            {
                "arm_group_label": "PRT064445", 
                "intervention_name": "PRT064445", 
                "intervention_type": "Biological", 
                "other_name": "Comparison of PRT064445 with placebo"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Healthy volunteers", 
        "lastchanged_date": "December 31, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tempe", 
                    "country": "United States", 
                    "state": "Arizona", 
                    "zip": "85283"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered PRT064445 After Dosing to Steady State With One of Four Direct/Indirect fXa Inhibitors in Healthy Volunteers", 
        "overall_contact": {
            "email": "fXaantidote@portola.com", 
            "last_name": "Study Clinical Trial Contact", 
            "phone": "855-256-7070"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Pharmacodynamics assessments(thrombin generation and anti-fXa activity)", 
            "safety_issue": "No", 
            "time_frame": "Multiple time points over 48 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01758432"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Pharmacokinetics: Plasma levels of PRT064445", 
            "safety_issue": "Yes", 
            "time_frame": "over 8 days following study drug administration"
        }, 
        "source": "Portola Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Portola Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}